Why Irish Med-Tech Startups Are Missing the Vision-Restoring Implant Opportunity
Prima, a California-based medical device company, received EU approval for its Prima photovoltaic subretinal implant in 2024. The device restores partial vision to patients with dry age-related macular degeneration, a condition affecting roughly 196 million people worldwide. Ireland has world-class researchers, a med-tech manufacturing base that employs over 45,000 people, and direct access to the EU single market. Yet the company that built that implant is from San Francisco, not Galway.
That gap is not a coincidence. It is a choice, made slowly and quietly, through a hundred smaller decisions about where to invest, what risk to take, and what kind of company is worth building.
The Market Is Real and It Is Already Here
The global medical device market is worth roughly €550 billion. To put that in perspective, that is more than the entire GDP of Ireland multiplied by four, generated every single year. The retinal implant segment alone is growing fast as populations age across Europe and demand for vision-preservation technology rises with them.
Ireland should be at the centre of this. Boston Scientific, Medtronic, Abbott and Cook Medical all have major operations here. The National University of Ireland Galway, now University of Galway, has been producing biomedical engineers for decades. The talent pipeline exists. The manufacturing know-how exists. The EU regulatory address exists. What is largely missing is the indigenous startup willing to do the hardest part: build the product from scratch and carry it through clinical validation.
Why Founders Avoid the Deep End
The honest answer is that founding a medical device company is brutally different from founding a software company. A SaaS product can go from idea to revenue in eighteen months. A Class III implantable device, the category a retinal prosthetic sits in, can take ten to fifteen years and cost north of €100 million before a single unit is sold commercially.
That is not a reason to avoid the space. It is a reason to understand what you are getting into before you start.
The fear is rational. The opportunity is bigger.
Four structural problems keep Irish founders out of this arena.
1. Capital is skewed toward shorter cycles. Irish venture capital, while growing, still favours software and fintech where returns come faster. The question of whether Irish VCs can back genuinely long-horizon bets is one the market has not fully answered. A retinal implant startup needs patient capital, the kind that waits a decade. That is a different conversation than most Irish seed rounds.
2. Regulatory literacy is low at founder level. The EU Medical Device Regulation, MDR 2017/745, replaced the older directive framework in 2021 and made an already demanding approval process significantly more rigorous. Notified Bodies, clinical evidence requirements, post-market surveillance obligations: founders who do not grow up inside a regulated industry rarely know this landscape exists until they hit it at speed. The regulation is not the enemy. Ignorance of it is.
3. Clinical partnerships take time to build and most founders do not start building them early enough. Prima spent years working with academic ophthalmology centres before it had a product to sell. The clinical relationship is not a distribution channel you bolt on at the end. It is part of the development process from day one. Irish academic hospitals are open to these partnerships. The founders who would benefit from them are often not knocking on the door.
4. The exit mindset arrives too early. Irish tech founders, as a cohort, have learned that the acquisition offer is often the best outcome available. That pattern makes sense in software, where a larger platform can absorb a small team and a codebase. In medical devices, acquirers buy proven products with clinical data, not early-stage teams with a prototype. Selling before scale in this sector means leaving nearly all the value on the table.
What the Producers Are Actually Doing
Prima's path is instructive because it is reproducible, not because it is magic.
The company identified a disease with no good treatment, dry AMD, and a patient population large enough to justify a decade of development. It built around a photovoltaic mechanism that required no external power pack or wearable camera in its subretinal form. It partnered with the Paris Vision Institute for early clinical work. It pursued CE marking through the EU pathway first, where the regulatory relationship with European ophthalmology centres gave it a natural advantage. It raised capital in tranches tied to clinical milestones, not on the back of projections alone.
None of those steps required being American. Every one of them is available to an Irish founder with the right scientific grounding and the patience to execute.
The producer's posture in medical devices is simple: find the unmet clinical need, build the evidence, and own the asset. The asset here is not the factory or the distribution deal. It is the clinical data that no competitor can replicate without running the same trials.
Where Ireland Actually Has an Edge
Ireland's regulatory address inside the EU is genuinely valuable for a medical device startup in a way it is not for a pure software business. CE marking gives access to over 450 million consumers without the additional cost and complexity of FDA approval as a first step. For a startup managing cash carefully across a long development cycle, that sequencing matters.
The semiconductor and advanced manufacturing infrastructure Ireland has been building also has direct relevance to implantable device manufacturing, where precision fabrication and clean-room capability are prerequisites. That infrastructure is here. The question is whether Irish founders connect the dots between what exists and what they could build on top of it.
Enterprise Ireland funds feasibility work and commercialisation through schemes that are specifically designed for high-potential startups in life sciences. Science Foundation Ireland backs the research end. The gap between publicly funded research and a funded device startup is real, but it is narrower than most founders assume.
The Stance
Ireland has every input required to produce the next Prima. It has the researchers, the manufacturing base, the regulatory address, and, increasingly, the capital infrastructure. What it lacks is founders willing to commit to a ten-year build in a sector where the eventual asset is worth something no software company can match: a patented, clinically validated implant that restores human sight.
Cheap software is not scarce. A device that gives someone their vision back is.
The choice between building something genuinely difficult and building something merely fast is the only choice that matters here. Pick the difficult thing.
